RT Journal Article
SR Electronic
T1 Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.13.21267471
DO 10.1101/2021.12.13.21267471
A1 Evans, Rachael A
A1 Leavy, Olivia C
A1 Richardson, Matthew
A1 Elneima, Omer
A1 McAuley, Hamish J C
A1 Shikotra, Aarti
A1 Singapuri, Amisha
A1 Sereno, Marco
A1 Saunders, Ruth M
A1 Harris, Victoria C
A1 Aul, Raminder
A1 Beirne, Paul
A1 Bolton, Charlotte E
A1 Brown, Jeremy S
A1 Choudhury, Gourab
A1 Bakerly, Nawar Diar
A1 Easom, Nicholas
A1 Echevarria, Carlos
A1 Fuld, Jonathan
A1 Hart, Nick
A1 Hurst, John R
A1 Jones, Mark
A1 Parekh, Dhruv
A1 Pfeffer, Paul
A1 Rahman, Najib M
A1 Rowland-Jones, Sarah
A1 Shah, Ajay M
A1 Wootton, Dan G
A1 Chalder, Trudie
A1 Davies, Melanie J
A1 De Soyza, Anthony
A1 Greenhalf, William
A1 Greening, Neil J
A1 Heaney, Liam G
A1 Heller, Simon
A1 Howard, Luke
A1 Jacob, Joseph
A1 Jenkins, R Gisli
A1 Lord, Janet M
A1 Man, Will D-C
A1 McCann, Gerry P
A1 Neubauer, Stefan
A1 Openshaw, Peter JM
A1 Porter, Joanna
A1 Quint, Jennifer
A1 Rowland, Matthew J
A1 Scott, Janet T
A1 Semple, Malcolm G
A1 Singh, Sally J
A1 Toshner, Mark
A1 Lewis, Keir
A1 Briggs, Andrew
A1 Docherty, Annemarie B
A1 Kerr, Steven
A1 Lone, Nazir I
A1 Sheikh, Aziz
A1 Thorpe, Mathew
A1 Zheng, Bang
A1 Chalmers, James D
A1 Ho, Ling-Pei
A1 Horsley, Alex
A1 Marks, Michael
A1 Poinasamy, Krisnah
A1 Raman, Betty
A1 Harrison, Ewen M
A1 Wain, Louise V
A1 Brightling, Christopher E
A1 Writing Group (on behalf of the PHOSP-COVID Collaborative Group)
YR 2021
UL http://medrxiv.org/content/early/2021/12/15/2021.12.13.21267471.abstract
AB Background There are currently no effective pharmacological or non-pharmacological interventions for Long-COVID. To identify potential therapeutic targets, we focussed on previously described four recovery clusters five months after hospital discharge, their underlying inflammatory profiles and relationship with clinical outcomes at one year.Methods PHOSP-COVID is a prospective longitudinal cohort study, recruiting adults hospitalised with COVID-19 across the UK. Recovery was assessed using patient reported outcomes measures (PROMs), physical performance, and organ function at five-months and one-year after hospital discharge. Hierarchical logistic regression modelling was performed for patient-perceived recovery at one-year. Cluster analysis was performed using clustering large applications (CLARA) k-medoids approach using clinical outcomes at five-months. Inflammatory protein profiling from plasma at the five-month visit was performed.Findings 2320 participants have been assessed at five months after discharge and 807 participants have completed both five-month and one-year visits. Of these, 35·6% were female, mean age 58·7 (SD 12·5) years, and 27·8% received invasive mechanical ventilation (IMV). The proportion of patients reporting full recovery was unchanged between five months 501/1965 (25·5%) and one year 232/804 (28·9%). Factors associated with being less likely to report full recovery at one year were: female sex OR 0·68 (95% CI 0·46-0·99), obesity OR 0·50 (95%CI 0·34-0·74) and IMV OR 0·42 (95%CI 0·23-0·76).Cluster analysis (n=1636) corroborated the previously reported four clusters: ‘very severe’, ‘severe’, ‘moderate/cognitive’, ‘mild’ relating to the severity of physical, mental health and cognitive impairments at five months in a larger sample. There was elevation of inflammatory mediators of tissue damage and repair in both the ‘very severe’ and the ‘moderate/cognitive’ clusters compared to the ‘mild’ cluster including interleukin-6 which was elevated in both comparisons. Overall, there was a substantial deficit in median (IQR) EQ5D-5L utility index from pre-COVID (retrospective assessment) 0·88 (0·74-1·00), five months 0·74 (0·60-0·88) to one year: 0·74 (0·59-0·88), with minimal improvements across all outcome measures at one-year after discharge in the whole cohort and within each of the four clusters.Interpretation The sequelae of a hospital admission with COVID-19 remain substantial one year after discharge across a range of health domains with the minority in our cohort feeling fully recovered. Patient perceived health-related quality of life remains reduced at one year compared to pre-hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials.Funding UKRI & NIHREvidence before this study We systematically searched PubMed and Embase databases for large studies reporting one-year follow-up data for hospitalised COVID-19 patients published between January 1, 2021 and November 7, 2021, without language restrictions. Search terms related to COVID-19, hospitalisation and long-term follow-up were used. A large prospective cohort study from Wuhan, China (n = 1276) showed that 49% of patients reported at least one persistent symptom during a follow-up clinic visit at 12 months post COVID-19; no significant improvement in exercise capacity was observed between 6- and 12-month visits. Another two large cohort studies in China (n = 2433) and Spain (n = 1950) with one-year follow-up data from telephone interviews showed that 45% and 81% of patients reported at least one residual COVID-19 symptom, respectively. However, no previous studies have compared the trajectories of COVID-19 recovery in patients classified by different clinical phenotypes, and there are no large studies investigating the relationship between systemic inflammation and ongoing health impairments post COVID-19.Added value of this study In a diverse population of adults post-hospital admission with COVID-19, our large UK prospective multi-centre study reports several novel findings: the minority felt fully recovered at one year with minimal recovery from five months across any health domain; female sex and obesity are associated with being less likely to feel fully recovered at one year; several inflammatory mediators were increased in individuals with the most severe physical, mental health, and cognitive impairments compared to individuals with milder ongoing impairments.Implications of all the available evidence Both pharmacological and non-pharmacological interventions are urgently needed to improve the ongoing burden following hospitalisation for COVID-19 both for individuals and healthcare systems; our findings support the use of a precision medicine approach with potential treatable traits of systemic inflammation and obesity.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.phosp.org Funding StatementPHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR);rapid response panel to tackle COVID-19 (grant references: MR/V027859/1 and COV0319). Core funding was provided by NIHR Leicester Biomedical Research Centre to support the PHOSP-COVID coordination team and NIHR Biomedical Research Centres (BRCs), Clinical Research Facilities (CRF) and NIHR Health Protection Research Unit (HPRU) and Translational Research Collaborations (TRCs) network across the country. The institutional funding that supports the outbreak labs that process the PHOSP samples NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE) and Liverpool Experimental Cancer Medicine Centre (grant reference: C18616/A25153)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Leeds West Research Ethics Committee (20/YH/0225) and is registered on the ISRCTN Registry (ISRCTN10980107).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript